Edition:
United States

Active Biotech AB (ACTI.ST)

ACTI.ST on Stockholm Stock Exchange

18.90SEK
23 Mar 2017
Change (% chg)

-- (--)
Prev Close
18.90kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
202,451
52-wk High
19.80kr
52-wk Low
7.96kr

Latest Key Developments (Source: Significant Developments)

Active Biotech Q4 operating loss narrows to SEK 13.5 mln
Thursday, 16 Feb 2017 02:30am EST 

Active Biotech Ab : Q4 net sales SEK 7.1 million versus SEK 5.0 million year ago . Q4 operating loss SEK 13.5 million versus SEK 28.2 million year ago .Says operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017.  Full Article

Active Biotech to raise SEK 55 mln via rights issue
Monday, 14 Nov 2016 01:28am EST 

Active Biotech Ab : Active biotech carries out rights issue of approximately 55 million Swedish crowns ($6.03 million) . Says subscription price amounts to 8 crowns per share . Says shareholders of the company have pre-emptive rights to subscribe for the new shares, whereby 13 existing shares entitle to subscription for one new share. Subscription for shares in the rights issue can only be made with pre-emptive rights . Subscription shall be made during the period 23 November - 7 December 2016 . Says rights issue is at no cost guaranteed in its entirety by Active Biotech's largest shareholder MGA Holding AB . The rights issue that now is conducted aims at providing Active Biotech with the financial stability required to await the outcome of the ongoing phase 3 study of laquinimod for the treatment of RRMS and the phase 2 study for the treatment of PPMS . If the outcome of these studies is positive, the Company expects that a positive operating result can be achieved from and including the financial year 2018 .Says proceeds from the rights issue, approximately SEK 55 million at full subscription, are intended to be used mainly for general working capital requirements.  Full Article

Active Biotech Q3 loss narrows
Monday, 14 Nov 2016 01:20am EST 

Active Biotech Ab : Active biotech AB interim report January - September 2016 . Q3 net sales SEK 4.1 million (5.2 mln) . Q3 operating loss SEK 11.1 million (loss of 22.2 mln) .Cash and cash equivalents at the end of the period SEK 39.9 million.  Full Article

Active Biotech AB says no dividend would be paid
Friday, 27 May 2016 02:33am EDT 

Active Biotech Ab : Annual general meeting of active biotech ab . In accordance with board of directors' proposal, it was resolved that no dividend would be paid .Board members and managing director were discharged from liability with respect to their management of company for 2015.  Full Article

Active Biotech plans to develop tasquinimod for treatment of multiple myeloma
Wednesday, 23 Mar 2016 03:40am EDT 

Active Biotech AB:Plans to develop tasquinimod for the treatment of multiple myeloma.Says patent application for the treatment of multiple myeloma with the company's compound tasquinimod will be public within short.Says with this application, treatment of multiple myeloma with tasquinimod is potentially protected until 2035.Preclinical program was performed and very good results were achieved in models for multiple myeloma.Says will actively seek a collaboration partner for the development of tasquinimod within this indication.During 2016 orphan drug status applications for tasquinimod treatment of multiple myeloma are planned to be submitted to authorities in the EU and USA.Multiple myeloma is an incurable form of blood cancer where the plasma cells in the bone marrow grow uncontrollably while other blood forming cells such as white and red blood cells and blood platelets are suppressed.Says total market for multiple myeloma drugs amounted to 7.8 billion usd in 2013 (globaldata 2015).  Full Article

Active Biotech says stops higher doses MS trials of Laquinimod
Monday, 4 Jan 2016 09:01am EST 

Active Biotech AB:Says Teva and Active Biotech announce discontinuation of higher doses of Laquinimod in two multiple sclerosis trials.Says ‍occurrence of cardiovascular events, none of which was fatal, in eight patients​.Says ‍both trials, concerto and arpeggio, are continuing lower-dose arms (0.6mg daily), and participants in trials will be provided with an update to confirm re-consent for participation​.  Full Article

Active Biotech to present final phase 3 study results for tasquinimod
Monday, 28 Sep 2015 03:00am EDT 

Active Biotech AB:Says final results from Active biotech's 10tasq10 phase 3 study of tasquinimod presented at the ECC conference.Says final results show that tasquinimod treatment resulted in a prolonged radiographic progression free survival (rPFS), 7.0 vs. 4.4 months (central assessment) similar to an earlier Phase 2 study.Says the positive effect on rPFS did not translate into an improved OS (HR 1.097, 95 pct CI: 0.938-1.282).Tasquinimod safety was in general manageable and similar to what was observed during the Phase 2 study.  Full Article

Active Biotech says patient enrollment in laquinimod trial completed
Thursday, 25 Jun 2015 08:01am EDT 

Active Biotech AB:Active Biotech: Teva and Active Biotech announce completion of patient enrollment in laquinimod phase III Concerto trial.Says Concerto study results are expected to be available toward mid-2017.  Full Article

Active Biotech AB plans redundancies of 47 employees, downsizes operations
Monday, 1 Jun 2015 04:01am EDT 

Active Biotech AB:Says focuses the operations on the laquinimod project and adjusts the organization.Made a notification of planned redundancies of 47 of employees, which means a down-sizing of operations.Operating costs are expected to decrease to about 50 million Swedish crowns per year, from 2016.Says planned organizational adjustment leads to substantially reduced operating costs.  Full Article

Active Biotech and Ipsen to stop development of Tasquinimod in prostate cancer
Thursday, 16 Apr 2015 01:00am EDT 

Active Biotech AB:Active Biotech and Ipsen SA announce their decision to discontinue the development of Tasquinimod in prostate cancer.Efficacy results together with preliminary safety data do not support positive benefit risk balance.Full results will be presented at an upcoming scientific conference.  Full Article

More From Around the Web